Skip to main content
    S

    Solid Biosciences LLC (SLDB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $6.48
    -0.36 (-5.26%)

    Market Cap: $763.42M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Solid Biosciences LLC (SLDB) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    Solid Biosciences LLC reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$174.32M, operating cash flow was -$156.29M and free cash flow was -$157.44M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$53.95M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $179.21M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0-100.0%N/AN/AN/A
    Dec 2022$8.09M-40.6%100.0%-1315.2%-1062.3%
    Dec 2021$13.62MN/A100.0%-530.5%-530.0%
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$0$0$0$8.09M$13.62M$0$0$0$0$0
    Gross profit$0$0$0$8.09M$13.62M$0$0$0$0$0
    Research and development$140.32M$96.43M$76.56M$78.42M$58.74M$64.88M$94.74M$57.97M$39.91M$20.12M
    Operating income-$179.21M-$129.73M-$104.25M-$106.45M-$72.25M-$88.41M-$119.32M-$75.69M-$54.86M-$25.58M
    Net income-$174.32M-$124.70M-$96.02M-$85.98M-$72.19M-$88.29M-$117.22M-$74.80M-$53.18M-$23.77M
    EBITDAN/AN/A-$102.98M-$85.96M-$68.17M-$84.39M-$116.26M-$73.94M-$52.74M-$23.58M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$3.12M$0$0$0$4.74M
    Gross profit$0$0$0-$467.00K$0$0$0-$488.00K$0$0$0-$587.00K
    Operating income-$57.66M-$57.38M-$57.31M-$49.40M-$48.06M-$41.69M-$40.05M-$39.90M-$35.18M-$27.79M-$26.86M-$22.27M
    Net income-$53.95M-$54.80M-$56.74M-$49.79M-$45.78M-$39.48M-$39.28M-$42.60M-$32.73M-$25.07M-$24.30M-$20.34M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $2.10M by $57.80M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$232.54M$188.66M$164.94M$260.25M$232.38M$171.17M$103.47M$139.60M$76.19M$40.64M
    Current assets$205.46M$157.30M$129.73M$219.64M$222.61M$158.90M$86.30M$128.64M$70.66M$39.97M
    Cash and equivalents$59.90M$80.23M$74.02M$155.38M$119.14M$154.74M$76.04M$86.37M$52.08M$7.68M
    Total liabilities$52.53M$51.42M$38.46M$48.59M$24.17M$39.08M$23.42M$14.41M$11.27M$78.52M
    Short-term debt$2.10M$3.02M$2.32M$2.56M$1.50M$2.21M$1.92M$346.00K$0N/A
    Shareholder equity$180.01M$137.25M$126.48M$211.67M$208.21M$132.09M$80.05M$125.18M-$59.26M-$84.36M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$389.90M$420.58M$422.89M$232.54M$273.91M$308.29M$343.90M$188.66M$211.83M$230.98M$248.69M$164.94M
    Total liabilities$47.79M$46.51M$48.76M$52.53M$55.97M$50.00M$49.44M$51.42M$44.80M$37.74M$37.97M$38.46M
    Cash and equivalents$125.97M$159.39M$297.10M$59.90M$61.36M$138.93M$210.63M$80.23M$64.39M$95.85M$117.57M$74.02M
    Shareholder equity$342.11M$374.07M$374.13M$180.01M$217.95M$258.29M$294.46M$137.25M$167.02M$193.25M$210.72M$126.48M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$156.29M-$100.01M-$94.18M-$97.98M-$77.76M-$56.60M-$92.71M-$70.20M-$43.22M-$20.12M
    Capital expenditures$1.15M$654.00K$1.51M$3.02M$1.28M$899.00K$4.39M$7.78M$2.28M$392.00K
    Free cash flow-$157.44M-$100.67M-$95.69M-$100.99M-$79.05M-$57.50M-$97.10M-$77.97M-$45.50M-$20.51M
    Share repurchases$0$5.11M$0N/AN/A$3.79M$2.10M$2.17M$2.42M$0
    Investing cash flow-$58.45M-$16.09M$9.69M$59.16M-$91.09M$6.60M$24.52M-$26.76M$10.45M-$4.05M
    Financing cash flow$194.45M$122.44M$3.12M$74.83M$134.99M$128.70M$57.88M$131.51M$77.08M$3.42M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$45.55M-$52.59M-$47.23M-$53.55M-$33.47M-$37.41M-$31.85M-$29.64M-$23.71M-$21.47M-$25.19M-$20.82M
    Capital expenditures$498.00K$150.00K$165.00K$565.00K$85.00K$377.00K$126.00K$204.00K$15.00K$286.00K$149.00K$90.00K
    Free cash flow-$46.04M-$52.74M-$47.40M-$54.12M-$33.56M-$37.79M-$31.98M-$29.85M-$23.72M-$21.75M-$25.34M-$20.91M
    Last 12 quarters

    Frequently Asked Questions About SLDB

    What is Solid Biosciences LLC's annual revenue?

    Solid Biosciences LLC reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Solid Biosciences LLC profitable?

    No. Solid Biosciences LLC reported net income of -$174.32M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does SLDB generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$156.29M minus capital expenditures of $1.15M produced free cash flow of -$157.44M.

    How much debt does Solid Biosciences LLC have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $2.10M and cash and equivalents of $59.90M.